Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.97 USD

26.97
2,911,983

-0.20 (-0.74%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $26.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in Exelixis (EXEL) Stock?

by Zacks Equity Research

Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately.

Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

by Zacks Equity Research

Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

by Zacks Equity Research

Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.

Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress

by Zacks Equity Research

Exelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated

by Zacks Equity Research

Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.

Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?

by Zacks Equity Research

Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EXEL vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug

by Zacks Equity Research

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.

GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia

by Zacks Equity Research

GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.

Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week

by Zacks Equity Research

Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene therapy for treating Danon Disease.

Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico

by Zacks Equity Research

Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor.

J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe

by Zacks Equity Research

J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway.

Bristol Myers' (BMY) Pulmonary Fibrosis Drug Positive in Phase II

by Zacks Equity Research

Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis.

Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study

by Zacks Equity Research

Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.

CymaBay (CBAY) Stock Up on Positive Results From PBC Study

by Zacks Equity Research

CymaBay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock up.

Illumina (ILMN) Down 14.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit

by Zacks Equity Research

The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.

Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.